Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prelude Therapeutics (PRLD) Net Cash Flow (2024 - 2025)

Prelude Therapeutics' Net Cash Flow history spans 2 years, with the latest figure at -$12.3 million for Q4 2025.

  • For Q4 2025, Net Cash Flow fell 1016.12% year-over-year to -$12.3 million; the TTM value through Dec 2025 reached $22.0 million, up 271.44%, while the annual FY2025 figure was $22.0 million, 271.44% up from the prior year.
  • Net Cash Flow for Q4 2025 was -$12.3 million at Prelude Therapeutics, down from $21.0 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $27.8 million in Q1 2025 and bottomed at -$16.7 million in Q3 2024.